

PATENT CASE INOU 157KD 5

...IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:) Examiner: Not assigned yet	RECEIVED
A. Saksena <i>et al</i> . Serial No.:09/909,062) Group Art Unit: Not assigned yet	JAN 0 4 2002
Filed: July 19, 2001)) Atty. Docket No.: IN01157K	ECH CENTER 1600/2900

For: NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS

Assistant Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

ż

It is requested that the following documents cited in the application, as listed below and in the accompanying form PTO-1449, be considered and made of record.

Documents cited in the Application:

U.S. 5,712,145 WO 89/04669 WO 98/17679 WO 98/22496 WO 99/07734 WO 00/09558 WO 00/09543 EP 381 216

Publications:

Pizzi et al. (1994) Proc. Natl. Acad. Sci (USA) 91:883-892
Failla et al. (1996) Folding & Design 1:35-42
Kollykhalov et al. (1994) J. Virol. 68:7525-7533
Komoda et al. (1994) J. Virol. 68:7351-7357
Landro et al. (1997) Biochem. 36:9340-9348
Ingallinella et al. (1998) Biochem. 37:8906-8914
Llinàs-Brunet et al. (1998) Bioorg. Med. Chem. Lett. 8:1713-1718
Martin et al. (1998) Biochem. 37:11459-11468
Dimasi et al. (1997) J. Virol. 71:7461-7469
Martin et al. (1997) Protein Eng. 10:607-614
Elzouki et al.) (1997) J. Hepat. 27:42-48
BioWorld Today 9(217): 4 (November 10, 1998)
Berenguer et al. (1998) Proc. Assoc. Am. Physicians 110(2):98-112
Hoofnagle et al. (1997) N. Engl. J. Med. 336:347
R. Zhang et al, Analytical Biochemistry, 270 (1999) 268-275

- D. L. Sali et al, Biochemistry, 37 (1998) 3392-3401
- K. Barlos et al, Int. J. Pept. Protein Res., 37 (1991), 513-520
- K. Holmberg et al, Acta Chem. Scand., <u>B33</u> (1979) 410-412
- A. Marchetti et al, Synlett., S1 (1999) 1000-1002
- W. Han et al, Bioorganic & Biomedicinal Chem Lett., 10 (2000) 711-713
- S. Agrawal *et al*, "Development and Characterization of Hepatitis C Virus Serine Protease Cell-based Trans-Cleavage Assay", *Hepatology* Supplement to Volume 30 (No. 4, Part 2, October 1999), *Abstract No. 615* (Proceedings of AASLD 50th Annual Meeting, Dallas, Texas, November 5-9, 1999.
 - L. Hughes, Org. Reactions, 42 (1992) 335.
 - R. F. Heck, Org. Reactions, 27 (1989) 345-390.

The submission of these documents is not to be presumed as an admission that these documents are prior art. The documents are being furnished solely for their possible utility in the examination of the present case. Since no Office Action has issued on the merits of this case, Applicants believe that no fee is due at this time. If, however, any fees are due, the Office may charge such fees to Deposit Account No. 19-0365.

If the Examiner has any questions, the Examiner is invited to contact the undersigned.

December 19, 2001 Schering-Plough Corporation 2000 Galloping Hill Road Patent Department, K-6-1,1990 Kenilworth, NJ 07033

Tel: (908) 298-5068 Fax: (908) 298-5388

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on

December 20, 2001

Palaiyur S. Kalyanaraman

Registered Representative

Signature and Date of Signature

Respectfully submitted,

Palaiyur S. Kalyanaraman Attorney for Applicants

Reg. No. 34,634

RECEIVED

JAN 0-4 2002

TECH CENTER 1600/2900 Sheet 1 of 1 U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO.: SERIAL NO.: PATENT AND TRADEMARK OFFICE IN01157K 09/909,062 APPLICANT: INFORMATION DISCLOSURE STATEMENT SAKSENA, et al BY APPLICANT FILING DATE: GROUP: (Use several sheets if necessary) To Be Assigned July 19, 2001 **U.S. PATENT DOCUMENTS** DOCUMENT DATE NAME CLASS SUB-FILING DATE IF **EXAMINER** INITIAL NUMBER CLASS APPROPRIATE AA U.S. 5,712,145 AB FOREIGN PATENT DOCUMENTS DOCUMENT COUNTRY CLASS SUB-TRANSLATION DATE NUMBER CLASS YES NO WO 89/04669 AC AD | WO 98/17679 ΑE WO 98/22496 ΑF WO 98/07734 AG WO 00/09558 WO 00/09543 AH EP 381 216 ΑI ΑJ AK OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) AL Pizzi, (1994) Proc. Natl. Acad. Sci(USA) 91:888-892 AM Failla (1996) folding & Design 1:35-42 AN Kollykhalov (1994) J. Virol. 68:7525-7533 AO Komoda (1994) J. Virol. 68:7351-7357 AP Landro (1997) Biochem 36:9340-9348 AQ | Ingallinella (1998) Biochem 37:8906-8914 AR | Llinas-Brunet (1998) Bioorg. Med. Chem. Lett, 8:1713-1718 AS Martin (1998) Biochem 37:11459-11468 AT Dimasi (1997) J. Virol. 71:7461-7469 Martin (1997) Protein Eng. 10:607-614 AU | Elzouki (1997) J. Hepat. 27:42-48 Bio World Today 9(217): 4 (November 10, 1998) AX Berenguer (1998) Proc. Assoc. Am. Physicians 110(2): 98-112 AY Hoofnagle (1997) New England Journal Med. 336:347 AZ Zhang (199) Analytical Biochemistry 270:268-275 BA | Sali (1998) Biochemistry 3392-3401 BB | Barlos (1991) Int. J. Pept. Protein Res 513-520 BC Holmberg (1979) Acta Chem. Scand., B33:410-412 BD Agrawal(1999) Hepatology Supplement to Vol 30 "Development and Characterization of Hepatitis C Virus Serine Protease Cell-based Trans-Cleavage Assay" BE Hughes (1992) Org. Reactions 42:335 Heck (1989) Org. Reactions 27:345-390 Han, (2000) Bioorganic & Medicinal Chemistry Letters 10 "α-Ketoamides, α-Ketoesters and α-Kiketones as HCV NS3 Protease Inhibitors" pp. 711-713. Marchetti(1999)Synlett, Vol. S1, "Synthesis of Two Novel Cyclic Biphenyl Ether Analogs of an Inhibitor of HCV NS3 Protease", pp 1000-1002. EXAMINER DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.